CAI · Caris Life Sciences, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $55.7M | Q2 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net loss -637K
-6.82M Interest income
+9.23M Interest expense
+0K Changes in fair value of financial instruments
+25.13M Other expense, net
+23K Income tax expense (benefit)
+6.54M Depreciation and amortization expense
+22.22M Stock-based compensation expense
= Adjusted EBITDA 55.68M
|
|||
| Caris Assure cases | 10,700 | Q2 2026 | — |
|
|
|||
| clinical cases | 59,200 | Q2 2026 | — |
| free cash flow non-GAAP | $6.4M | Q2 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net cash provided by (used in) operating activities 28.48M
-22.08M Less: capitalized software and purchases of property and equipment
= Free cash flow 6.4M
|
|||
| MI Profile cases | 48,300 | Q2 2026 | — |
|
|
|||
| total oncology tests | 345,000 | Q2 2026 | — |
| whole exome/whole transcriptome tests | 114,000 | Q2 2026 | — |
| clinical therapy selection cases | 52,800 | Q1 2026 | — |
|
|
|||
| Total matched profiles | 790,000 | Q1 2026 | — |
| Total profiles | 1,070,000 | Q1 2026 | — |
| Whole Exome profiles | 677,000 | Q1 2026 | — |
| Whole Transcriptome profiles | 728,000 | Q1 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CAI
this stock
Caris Life Sciences, Inc.
|
$6.16B | -19.2% | +97.0% | — | 5.2% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CAI | -4.1% | +32.2% | +23.6% | +39.1% | -19.2% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -4.5% | +27.8% | +9.8% | +35.2% | -33.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.